Literature DB >> 2499590

Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine.

J P Raymond1, M Izembart, V Marliac, F Dagousset, R E Merceron, M Vulpillat, G Vallée.   

Abstract

We studied ovarian function retrospectively in 66 women who had regular menstrual cycles before undergoing complete thyroidectomy for differentiated thyroid cancer and subsequent thyroid remnant ablation with 131I. Eighteen women developed temporary amenorrhea accompanied by increased serum gonadotropin concentrations during the first year after 131I therapy. No correlation was found between the radioactive iodine dose absorbed, thyroid uptake before treatment, oral contraceptive use, or thyroid autoimmunity. Only age was a determining factor, with the older women being the most affected. We conclude that radioiodine ablation therapy is followed by transient ovarian failure, especially in older women.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499590     DOI: 10.1210/jcem-69-1-186

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Radioiodine for hyperthyroidism.

Authors:  D O'Halloran; S M Shalet
Journal:  BMJ       Date:  1992-11-07

2.  Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.

Authors:  A S Alzahrani; G Mohamed; A Al Shammary; S Aldasouqi; S Abdal Salam; M Shoukri
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

3.  Retrospective evaluation of the dose received by the ovary after radioactive iodine therapy for thyroid cancer.

Authors:  M Izembart; J Chavaudra; B Aubert; G Vallée
Journal:  Eur J Nucl Med       Date:  1992

Review 4.  Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer.

Authors:  L Vini; S Hyer; A Al-Saadi; B Pratt; C Harmer
Journal:  Postgrad Med J       Date:  2002-02       Impact factor: 2.401

5.  Clinical presentations of thyroid cancer patients with multiple primary cancers.

Authors:  J D Lin; K J Lin; T C Chao; C Hseuh; N M Tsang; B Y Huang
Journal:  J Endocrinol Invest       Date:  2011-05-24       Impact factor: 4.256

6.  Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer.

Authors:  Massimo Giusti; Miranda Mittica; Paola Comite; Claudia Campana; Stefano Gay; Michele Mussap
Journal:  Endocrine       Date:  2018-01-04       Impact factor: 3.633

7.  Use of radioactive iodine for thyroid cancer.

Authors:  Megan R Haymart; Mousumi Banerjee; Andrew K Stewart; Ronald J Koenig; John D Birkmeyer; Jennifer J Griggs
Journal:  JAMA       Date:  2011-08-17       Impact factor: 56.272

Review 8.  Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer.

Authors:  Erin F Wolff; Marybeth Hughes; Maria J Merino; James C Reynolds; Jeremy L Davis; Craig S Cochran; Francesco S Celi
Journal:  Thyroid       Date:  2010-09       Impact factor: 6.568

9.  Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations.

Authors:  D Casara; D Rubello; G Saladini; A Piotto; M R Pelizzo; M E Girelli; B Busnardo
Journal:  Eur J Nucl Med       Date:  1993-03

10.  Outcome of pregnancy after radioactive iodine treatment for well differentiated thyroid carcinomas.

Authors:  J D Lin; H S Wang; H F Weng; P F Kao
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.